Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

1467465

registered interest
date	01/06/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what monitoring and data systems are in place to evaluate the effectiveness of emergency treatments administered to patients vulnerable to covid-19.
tabling member constituency	Harrow East
tabling member printed	Bob Blackman
uin	11649
answer	answer is ministerial correction date of answer 14/06/2022 answer text <p>NHS England and NHS Improvement collect data on treatments for eligible patients hospitalised due to COVID-19, hospital-onset COVID-19 and non-hospitalised patients treated through COVID Medicines Delivery Units. Data is collected on the numbers of treatments prescribed and administered and published weekly at the following link:</p><p><a href="https://www.england.nhs.uk/statistics/statistical-work-areas/covid-therapeutics-antivirals-and-neutralising-monoclonal-antibodies/" target="_blank">https://www.england.nhs.uk/statistics/statistical-work-areas/covid-therapeutics-antivirals-and-neutralising-monoclonal-antibodies/</a></p><p>Data is also collected on hospitalisation rates for treated and untreated patients. NHS England and NHS Improvement continue to work with the research community to monitor this observational data and understand the impact of treatments on patient outcomes.</p> answering member constituency Erewash answering member printed Maggie Throup question first answered 14/06/2022 16:22:05 answering member 4447 label Biography information for Maggie Throup
tabling member	4005 label Biography information for Bob Blackman

1467466

registered interest
date	01/06/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to the US FDA's withdrawal of authorisation for the use of Sotrovimab for treatment of covid-19 on 5 April 2022, what steps he is taking to ensure the (a) stringency and (b) consistency of his Department's reviews of (i) Evusheld and (ii) other covid-19 treatments.
tabling member constituency	Harrow East
tabling member printed	Bob Blackman
uin	11650
answer	answer is ministerial correction date of answer 21/06/2022 answer text <p>The Antivirals and Therapeutics Taskforce engages with other nations to share learning on the use, deployment and evaluation of COVID-19 therapeutics and antivirals which may inform policy. The UK Health Security Agency is monitoring the effectiveness of all COVID-19 therapeutics, including sotrovimab. The RAPID C-19 collaborative, the National Health Service and other relevant experts provide advice to the United Kingdom Chief Medical Officers on whether treatments should be recommended for deployment, taking account of all available evidence.</p><p>The Department is currently reviewing prophylaxis and the efficacy of Evusheld. The Therapeutics Clinical Review Panel provides advice on the appropriate patient cohorts for potential new COVID-19 therapies, including preventative treatments. Final clinical policies and eligibility would be proposed by the NHS and agreed by the UK Chief Medical Officers.</p><p> </p> answering member constituency Erewash answering member printed Maggie Throup question first answered 21/06/2022 10:16:47 answering member 4447 label Biography information for Maggie Throup
tabling member	4005 label Biography information for Bob Blackman

1467486

registered interest
date	01/06/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Dementia: Diagnosis
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answet of 31 May 2022 to Question 6744 on dementia diagnosis, what assessment he has made of the impact the £17 million in funding to clinical commissioning groups on dementia diagnosis rates in England.
tabling member constituency	Harrow East
tabling member printed	Bob Blackman
uin	11651
answer	answer is ministerial correction date of answer 13/06/2022 answer text <p><strong> </strong></p><p>No formal assessment has been made as the full impact of the funding cannot yet be determined. NHS England and NHS Improvement continue to monitor the monthly diagnosis rate and are analysing trends at regional and sustainability and transformation partnership level to aid targeted recovery efforts. Work to improve dementia diagnosis rates will continue in 2022/23. We will set out plans for dementia in England for the next 10 years later this year, including on diagnosis, risk reduction and prevention and research.</p> answering member constituency Chichester answering member printed Gillian Keegan question first answered 13/06/2022 12:14:24 answering member 4680 label Biography information for Gillian Keegan
tabling member	4005 label Biography information for Bob Blackman